We are live on ! Find out more
BLFS icon

BioLife Solutions

149 hedge funds and large institutions have $823M invested in BioLife Solutions in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,047% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $342K

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

11% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 46

11% more capital invested

Capital invested by funds: $743M → $823M (+$79.8M)

6% more funds holding

Funds holding: 140149 (+9)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3.5% less ownership

Funds ownership: 101.53%98.03% (-3.5%)

Holders
149
Holders Change
+9
Holders Change %
+6.43%
% of All Funds
2.15%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
51
Reduced
46
Closed
9
Calls
$3.92M
Puts
$342K
Net Calls
+$3.58M
Net Calls Change
+$357K
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$162M
BlackRock
2
BlackRock
New York
$101M +$679K +38,854 +0.7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$53.2M +$5.19M +296,727 +12%
Millennium Management
4
Millennium Management
New York
$33.6M -$8.74M -499,600 -22%
William Blair Investment Management
5
William Blair Investment Management
Illinois
$32M +$241K +13,785 +0.8%
FAM
6
Fred Alger Management
New York
$27.6M -$2.36M -134,738 -8%
State Street
7
State Street
Massachusetts
$24.1M +$861K +49,223 +4%
Invesco
8
Invesco
Georgia
$23.7M +$1.61M +91,858 +8%
PCM
9
Palisade Capital Management
New Jersey
$23.2M +$685K +39,168 +3%
CRM
10
Cramer Rosenthal McGlynn
Connecticut
$21.7M +$20.4M +1,167,228 New
Ameriprise
11
Ameriprise
Minnesota
$20.7M -$5M -285,784 -20%
GIM
12
Granahan Investment Management
Massachusetts
$20M -$3.72M -212,830 -16%
GCM
13
Geneva Capital Management
Wisconsin
$16.3M +$100K +5,730 +0.7%
PCM
14
Portolan Capital Management
Massachusetts
$16.2M +$6.11M +349,631 +67%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$14.6M +$542K +31,022 +4%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$13.5M +$1.93M +110,421 +18%
GS
17
Gagnon Securities
New York
$11M -$596K -34,087 -5%
Citadel Advisors
18
Citadel Advisors
Florida
$10.4M +$106K +6,085 +1%
RA
19
Royce & Associates
New York
$9.56M -$6.23M -356,396 -41%
Bank of America
20
Bank of America
North Carolina
$9.21M +$3.25M +185,611 +60%
SIMG
21
Stephens Investment Management Group
Texas
$8.36M +$1.41M +80,378 +22%
CRC
22
Curi RMB Capital
Illinois
$7.81M +$393K +22,455 +6%
New York State Common Retirement Fund
23
New York State Common Retirement Fund
New York
$7.8M
Morgan Stanley
24
Morgan Stanley
New York
$7.35M -$5.33M -305,026 -44%
MIM
25
Meros Investment Management
Texas
$7.29M +$17.5K +999 +0.3%

BLFS Hedge Fund Activity: Q1 2024 in Review

149 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q1 2024, worth a combined $823M — up 11% from $743M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BLFS positions and 9 closed out — a net gain of 9 holders — while 51 added to existing stakes and 46 trimmed.

The largest buyer was Cramer Rosenthal McGlynn, opening a new position worth an estimated $20.4M. The largest seller was Goldman Sachs, cutting an estimated $39.4M.

  • 149 institutional investors held BioLife Solutions (BLFS) as of Q1 2024, up from 140 in Q4 2023.
  • Funds reported $823M of BioLife Solutions stock for Q1 2024, up 11% quarter-over-quarter.
  • 18 funds opened new BioLife Solutions positions in Q1 2024 and 9 closed out, a net change of +9 holders.
  • The largest BioLife Solutions buyer in Q1 2024 was Cramer Rosenthal McGlynn, an estimated $20.4M added.
  • The largest BioLife Solutions seller in Q1 2024 was Goldman Sachs, an estimated $39.4M sold.

Based on aggregated 13F filings for Q1 2024.